Stay updated on Copanlisib and Nivolumab in Lymphoma Clinical Trial
Sign up to get notified when there's something new on the Copanlisib and Nivolumab in Lymphoma Clinical Trial page.

Latest updates to the Copanlisib and Nivolumab in Lymphoma Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe webpage has undergone significant updates, including the removal of detailed descriptions of a clinical trial involving copanlisib and nivolumab for treating relapsed/refractory diffuse large B-cell lymphoma, while adding new identifiers and a revision number.SummaryDifference59%
- Check29 days agoChange DetectedThe web page has updated its version from v2.14.3 to v2.14.4, and the date has changed from March 25, 2025, to March 3, 2025.SummaryDifference0.2%
- Check37 days agoChange DetectedThe page has been updated to reflect a new last update date of March 25, 2025, and a revision change to version 2.14.3, replacing the previous date of March 3, 2025, and version 2.14.2.SummaryDifference0.1%
- Check44 days agoChange DetectedDifference0.2%
- Check66 days agoChange DetectedThe page has updated several important dates, including the addition of specific dates in 2025 and the removal of previous estimated dates.SummaryDifference0.7%
Stay in the know with updates to Copanlisib and Nivolumab in Lymphoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Copanlisib and Nivolumab in Lymphoma Clinical Trial page.